| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2013-05-28 | lirilumab or IPH2102/BMS-986015 in combination with Anti-PD-1 (BMS-936558) | advanced solid tumors | 1 | BMS (USA - NY) Innate Pharma (France) | Cancer - Oncology |
| 2013-05-22 | Prolastin-C (Alpha1-Proteinase Inhibitor [Human]) | alpha-1 antitrypsin deficiency (AATD) |
Grifols (Spain) | Liver diseases - Genetic diseases - Respiratory diseases - Rare diseases | |
| 2013-05-21 | dupilumab | asthma | 2a | Sanofi (France) Regeneron Pharmaceuticals (USA) | Respiratory diseases - Inflammatory diseases - Allergic diseases |
| 2013-05-21 | tiotropium* Respimat® | asthma | 3 | Boehringer Ingelheim (Germany) | Allergic diseases - Inflammatory diseases - Respiratory diseases |
| 2013-05-20 | PM01183 (lurbinectidin) in combination with capecitabine | advanced solid tumors | 1b | PharmaMar (Spain) | Cancer - Oncology |
| 2013-05-20 | XF-73 - exeporfinium chloride | Staphylococcus aureus | 1 | Destiny Pharma (UK) | Infectious diseases |
| 2013-05-20 | riociguat | pulmonary arterial hypertension (PAH) |
3 | Bayer HealthCare (Germany) | Rare diseases - Cardiovascular diseases |
| 2013-05-17 | Afinitor® (everolimus) | HER2 positive advanced breast cancer |
3 | Novartis (Switzerland) | Cancer - Oncology |
| 2013-05-17 | N9-GP (glycopegylated recombinant factor IX) | hemophilia B | 3 | Novo Nordisk (Denmark) | Genetic diseases- Hematological diseases |
| 2013-05-16 | MPDL3280A (atezolizumab) | non-small cell lung cancer (NSCLC) |
Roche (Switzerland) | Cancer - Oncology | |
| 2013-05-16 | moxetumomab pasudotox | unresponsive or relapsed hairy cell leukaemia | 3 | AstraZeneca (UK) | Cancer - Oncology |
| 2013-05-16 | olaparib | ovarian cancer | 2 | AstraZeneca (UK) | Cancer - Oncology |
| 2013-05-16 | selumetinib | advanced melanoma | 2 | AstraZeneca (UK) | Cancer - Oncology |
| 2013-05-16 | etrolizumab | moderate-to-severely active ulcerative colitis | 2 | Roche (Switzerland) | Autoimmune diseases - Inflammatory diseases |
| 2013-05-16 | ²¹²Pb-TCMC-Trastuzumab | HER-2 positive intra-abdominal cancers | 1 | Areva Med (France) | Cancer - Oncology |
| 2013-05-16 | EndoTAG®-1 | hormone-receptor-positive, HER2-negative breast cancer | 2 | Medigene (Germany) | Cancer - Oncology |
| 2013-05-15 | regorafenib (BAY 73-4506) | hepatocellular carcinoma (HCC) | 3 | Bayer Healthcare (Germany) | Cancer - Oncology |
| 2013-05-15 | Epi proColon® (colorectal cancer blood test) | colorectal cancer detection | Epigenomics (Germany - USA) | Cancer - Oncology | |
| 2013-05-13 | PM01183 (lurbinectidin) in combination with doxorubicin | 1b | PharmaMar (Spain) | ||
| 2013-05-13 | PLX-PAD Cells (Placental eXpanded cells) | preeclampsia |
preclinical | Pluristem Therapeutics (Israel) | Renal diseases - Cardiovascular diseases - Women health |
